In adult zebrafish, MCFAs treatment mitigated CML-induced acute death and swimming abnormalities, and substantially augmented plasma sulfhydryl content, ferric ion reduction ability (FRA), and paraoxonase (PON)-like activity. This evidence concerns the gene PON1 and chronic myelogenous leukemia, BCR-ABL1 positive.